Adjuvant therapy of gastrointestinal stromal tumors (GIST)

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Opinion statement: Imatinib was proven to be effective for the adjuvant treatment of localized, surgically excised, gastrointestinal stromal tumors (GIST). Currently, there is proof that it is able to delay relapse and prolong survival. An effect on cure rate of localized GIST is still to be proven, given the shape of relapse-free survival curves, which apparently tend to overlap after 2-3 years from completion of the adjuvant period. Although observation for a longer follow-up is needed, attempts to prolong adjuvant therapy beyond the currently standard 3 years have been made and the results are awaited. However, the impact of more prolonged adjuvant intervals on secondary resistance is unknown, so that standard practice is still 3 years in most institutions. The adjuvant choice should be based on a rather precise identification of the relapse risk of the single patient, reserving treatment to the high-risk subgroups. The choice also should be personalized on the basis of genotype: generally, PDGFRA D842V mutated and wild-type GIST are excluded. Additional results from completed trials on a longer follow-up are awaited to further refine such "precision" decision-making. There are several instances in which part of the "adjuvant" treatment may be administered preoperatively, even on the face of a surgically resectable GIST, to make surgery more limited and/or safer.

Original languageEnglish
Pages (from-to)277-284
Number of pages8
JournalCurrent Treatment Options in Oncology
Volume13
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Gastrointestinal Stromal Tumors
Recurrence
Survival
Therapeutics
Decision Making
Genotype
Observation

Keywords

  • Adjuvant therapy
  • Gastrointestinal stromal tumors
  • Imatinib

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

@article{82b4366edc3d46eb9dea30c72651d476,
title = "Adjuvant therapy of gastrointestinal stromal tumors (GIST)",
abstract = "Opinion statement: Imatinib was proven to be effective for the adjuvant treatment of localized, surgically excised, gastrointestinal stromal tumors (GIST). Currently, there is proof that it is able to delay relapse and prolong survival. An effect on cure rate of localized GIST is still to be proven, given the shape of relapse-free survival curves, which apparently tend to overlap after 2-3 years from completion of the adjuvant period. Although observation for a longer follow-up is needed, attempts to prolong adjuvant therapy beyond the currently standard 3 years have been made and the results are awaited. However, the impact of more prolonged adjuvant intervals on secondary resistance is unknown, so that standard practice is still 3 years in most institutions. The adjuvant choice should be based on a rather precise identification of the relapse risk of the single patient, reserving treatment to the high-risk subgroups. The choice also should be personalized on the basis of genotype: generally, PDGFRA D842V mutated and wild-type GIST are excluded. Additional results from completed trials on a longer follow-up are awaited to further refine such {"}precision{"} decision-making. There are several instances in which part of the {"}adjuvant{"} treatment may be administered preoperatively, even on the face of a surgically resectable GIST, to make surgery more limited and/or safer.",
keywords = "Adjuvant therapy, Gastrointestinal stromal tumors, Imatinib",
author = "Casali, {Paolo G.} and Elena Fumagalli and Alessandro Gronchi",
year = "2012",
month = "9",
doi = "10.1007/s11864-012-0198-0",
language = "English",
volume = "13",
pages = "277--284",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Adjuvant therapy of gastrointestinal stromal tumors (GIST)

AU - Casali, Paolo G.

AU - Fumagalli, Elena

AU - Gronchi, Alessandro

PY - 2012/9

Y1 - 2012/9

N2 - Opinion statement: Imatinib was proven to be effective for the adjuvant treatment of localized, surgically excised, gastrointestinal stromal tumors (GIST). Currently, there is proof that it is able to delay relapse and prolong survival. An effect on cure rate of localized GIST is still to be proven, given the shape of relapse-free survival curves, which apparently tend to overlap after 2-3 years from completion of the adjuvant period. Although observation for a longer follow-up is needed, attempts to prolong adjuvant therapy beyond the currently standard 3 years have been made and the results are awaited. However, the impact of more prolonged adjuvant intervals on secondary resistance is unknown, so that standard practice is still 3 years in most institutions. The adjuvant choice should be based on a rather precise identification of the relapse risk of the single patient, reserving treatment to the high-risk subgroups. The choice also should be personalized on the basis of genotype: generally, PDGFRA D842V mutated and wild-type GIST are excluded. Additional results from completed trials on a longer follow-up are awaited to further refine such "precision" decision-making. There are several instances in which part of the "adjuvant" treatment may be administered preoperatively, even on the face of a surgically resectable GIST, to make surgery more limited and/or safer.

AB - Opinion statement: Imatinib was proven to be effective for the adjuvant treatment of localized, surgically excised, gastrointestinal stromal tumors (GIST). Currently, there is proof that it is able to delay relapse and prolong survival. An effect on cure rate of localized GIST is still to be proven, given the shape of relapse-free survival curves, which apparently tend to overlap after 2-3 years from completion of the adjuvant period. Although observation for a longer follow-up is needed, attempts to prolong adjuvant therapy beyond the currently standard 3 years have been made and the results are awaited. However, the impact of more prolonged adjuvant intervals on secondary resistance is unknown, so that standard practice is still 3 years in most institutions. The adjuvant choice should be based on a rather precise identification of the relapse risk of the single patient, reserving treatment to the high-risk subgroups. The choice also should be personalized on the basis of genotype: generally, PDGFRA D842V mutated and wild-type GIST are excluded. Additional results from completed trials on a longer follow-up are awaited to further refine such "precision" decision-making. There are several instances in which part of the "adjuvant" treatment may be administered preoperatively, even on the face of a surgically resectable GIST, to make surgery more limited and/or safer.

KW - Adjuvant therapy

KW - Gastrointestinal stromal tumors

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=84865686981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865686981&partnerID=8YFLogxK

U2 - 10.1007/s11864-012-0198-0

DO - 10.1007/s11864-012-0198-0

M3 - Article

C2 - 22743760

AN - SCOPUS:84865686981

VL - 13

SP - 277

EP - 284

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 3

ER -